At the J.P. Morgan Healthcare Conference in 2023, Bayer AG forecast that four commercial and late-stage products would generate peak revenues totaling €12bn, including €5bn alone from Factor XIa inhibitor asundexian for atrial fibrillation (AF) and stroke and €1bn for neurokinin-1,3 (NK-1,3) receptor antagonist elinzanetant for vasomotor symptoms in women going through menopause. A year later, the company has positive Phase III results for elinzanetant, but after suffering a setback for asundexian.
Bayer Sees Significant, But Smaller, Asundexian Opportunity
BMS Still Confident In Competing Asset Milvexian
Scrip spoke with Bayer’s head of pharma R&D Christian Rommel at the J.P. Morgan Healthcare Conference about the road ahead for Factor XIa inhibitor asundexian after its atrial fibrillation setback.
More from Clinical Trials
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
More from R&D
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.